Intuitive Surgical (NASDAQ:ISRG) Raised to Buy at Redburn Atlantic

Redburn Atlantic upgraded shares of Intuitive Surgical (NASDAQ:ISRG) from a neutral rating to a buy rating in a research note released on Friday, Marketbeat Ratings reports. Redburn Atlantic currently has $510.00 price objective on the medical equipment provider’s stock, up from their previous price objective of $380.00.

Other research analysts have also issued reports about the company. Truist Financial upped their price target on Intuitive Surgical from $450.00 to $515.00 and gave the company a buy rating in a research report on Tuesday, July 16th. Citigroup increased their price target on shares of Intuitive Surgical from $462.00 to $512.00 and gave the stock a buy rating in a research report on Wednesday, July 10th. Jefferies Financial Group boosted their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a hold rating in a research report on Friday, April 19th. Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a buy rating in a research report on Friday, July 19th. Finally, Barclays upped their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an overweight rating in a research note on Thursday, July 18th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $442.30.

Intuitive Surgical Trading Up 2.2 %

ISRG stock traded up $9.70 during mid-day trading on Friday, reaching $447.70. 1,305,907 shares of the stock traded hands, compared to its average volume of 1,570,972. Intuitive Surgical has a 52-week low of $254.85 and a 52-week high of $468.78. The stock’s fifty day moving average is $432.79 and its 200-day moving average is $402.15. The company has a market cap of $158.80 billion, a P/E ratio of 79.06, a P/E/G ratio of 4.97 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the firm earned $1.18 EPS. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. Equities research analysts expect that Intuitive Surgical will post 5.22 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares in the company, valued at $5,441,507.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mark Brosius sold 175 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the transaction, the senior vice president now owns 883 shares in the company, valued at $343,628.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,005 shares of company stock valued at $6,894,422. 0.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Strategic Financial Concepts LLC lifted its holdings in shares of Intuitive Surgical by 40,221.4% during the 2nd quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock valued at $1,184,000 after purchasing an additional 265,461 shares in the last quarter. Umpqua Bank boosted its holdings in shares of Intuitive Surgical by 3.7% in the second quarter. Umpqua Bank now owns 3,116 shares of the medical equipment provider’s stock valued at $1,386,000 after buying an additional 112 shares during the period. Norden Group LLC increased its position in shares of Intuitive Surgical by 29.6% during the second quarter. Norden Group LLC now owns 1,240 shares of the medical equipment provider’s stock worth $552,000 after acquiring an additional 283 shares in the last quarter. Cobblestone Capital Advisors LLC NY lifted its position in Intuitive Surgical by 13.9% in the 2nd quarter. Cobblestone Capital Advisors LLC NY now owns 1,226 shares of the medical equipment provider’s stock valued at $545,000 after acquiring an additional 150 shares in the last quarter. Finally, SRS Capital Advisors Inc. boosted its stake in Intuitive Surgical by 13.8% in the 2nd quarter. SRS Capital Advisors Inc. now owns 3,246 shares of the medical equipment provider’s stock worth $1,444,000 after purchasing an additional 393 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.